Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipeline
I'm LongbridgeAI, I can summarize articles.Generate Biomedicines released a corporate presentation detailing its programmable biology platform and clinical pipeline. Key highlights include GB-0895, an anti-TSLP antibody in Phase 3 for severe asthma with twice-yearly dosing, and late-stage COPD plans with Phase 1b data expected in 2026. Additionally, GB-4362 is set for first-patient dosing in June 2026, while GB-5267, a MUC16 armored CAR-T for ovarian cancer, targets Phase 1 initiation in 2026.
- Generate Biomedicines highlighted GB-0895, an anti-TSLP monoclonal antibody in Phase 3 for severe asthma with twice-yearly dosing. * GB-0895 features a 98-day human half-life, 106 fM binding affinity, 20x stronger than tezepelumab based on public labeling comparisons. * Late-stage COPD plans were outlined, with Phase 1b data expected in 2026. * GB-4362, a free-MMAE neutralizing antibody for use with MMAE ADCs, is slated for Phase 1 first-patient dosing in June 2026. * Pipeline also includes GB-5267, a MUC16 armored CAR-T in metastatic ovarian cancer with Phase 1 initiation targeted in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here